[{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ifx-1","moa":"Complement 5a receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ifx-1","moa":"Complement factor C5a","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ifx-1","moa":"Complement factor C5a","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Ifx-1","moa":"Complement factor C5a","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"Complement 5a receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"Complement 5a receptor","graph1":"Oncology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"Complement 5a receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"C5a","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"German Federal Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Funding","leadProduct":"Vilobelimab","moa":"Complement 5a receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InflaRx","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ German Federal Government","highestDevelopmentStatusID":"12","companyTruncated":"InflaRx \/ German Federal Government"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Pembrolizumab","moa":"Complement 5a receptor","graph1":"Oncology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"Complement 5a receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Innovaderm Research","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"Complement 5a receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Innovaderm Research","highestDevelopmentStatusID":"10","companyTruncated":"InflaRx \/ Innovaderm Research"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"Complement 5a receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"Complement 5a receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"C5a","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"Complement 5a receptor","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"Complement 5a receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"Complement 5a receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"Complement 5a receptor","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"INF904","moa":"Complement C5","graph1":"Immunology","graph2":"Phase I","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Staidson Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"BDB-001","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Staidson Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"InflaRx \/ Staidson Biopharma"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Vilobelimab","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InflaRx","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Injectable\/Injection","sponsorNew":"InflaRx \/ Raymond James & Associates","highestDevelopmentStatusID":"12","companyTruncated":"InflaRx \/ Raymond James & Associates"},{"orgOrder":0,"company":"InflaRx","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Vilobelimab","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InflaRx","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Injectable\/Injection","sponsorNew":"InflaRx \/ Raymond James & Associates","highestDevelopmentStatusID":"12","companyTruncated":"InflaRx \/ Raymond James & Associates"},{"orgOrder":0,"company":"InflaRx","sponsor":"Raymond James & Associates","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Vilobelimab","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InflaRx","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Raymond James & Associates","highestDevelopmentStatusID":"12","companyTruncated":"InflaRx \/ Raymond James & Associates"},{"orgOrder":0,"company":"InflaRx","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"Vilobelimab","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ InflaRx","highestDevelopmentStatusID":"12","companyTruncated":"InflaRx \/ InflaRx"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"INF904","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"INF904","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Vilobelimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"InflaRx \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by InflaRx
Details :
INF904 is an orally administered low molecular weight C5aR inhibitor which is under phase 1 clinical development for the treatment of inflammatory diseases.
Details :
Gohibic (vilobelimab) is a first-in-class monoclonal anti-human complement factor C5a antibody, which demonstrates high selectivity towards its target in human blood, investigated for the treatment of Pyoderma Gangrenosum.
Details :
INF904 is an orally administered small molecule inhibitor of C5a-induced signaling via the receptor C5aR, which is investigated for the treatment of inflammatory diseases.
Details :
Gohibic (vilobelimab) is a first-in-class monoclonal anti-human complement factor C5a antibody, which demonstrates high selectivity towards its target in human blood, used for the treatment of Critically Ill COVID-19 Patients.
Details :
Gohibic (vilobelimab) is a first-in-class monoclonal anti-human complement factor C5a antibody that has been granted an approval for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilat...
Details :
Under the terms of the agreement, WuXi Biologics will provide cGMP manufacturing of Gohibic (vilobelimab), a first-in-class monoclonal anti-human complement factor C5a antibody for the treatment of COVID-19.
Details :
The Company intends to use the net proceeds from the offering to fund the continued development of IFX-1 (vilobelimab), a chimeric monoclonal IgG4 antibody that specifically binds with high affinity to the soluble form of human C5a.
Details :
The Company intends to use the net proceeds from the offering to fund the continued development of IFX-1 (vilobelimab),a chimeric monoclonal IgG4 antibody that specifically binds with high affinity to the soluble form of human C5a.
Details :
The Company intends to use the net proceeds from the offering to fund the continued development of IFX-1 (vilobelimab), an anti-C5a monoclonal antibody, in patients with severe COVID-19.
Reset All
